$BIOA
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It also develops BGE-100, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.
Healthcare
Sector
Biotechnology
Industry
Kristen Fortney
CEO
62
Employees
$19.30
Current Price
$722.12M
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 1 | $150,889.90 | 7,433 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 2 | $290,258.65 | 14,866 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 3 | 8 | $5,140,612.95 | 282,406 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Mar 2, 2026 | RUBIN PAUL D Chief Medical Officer | Sale | 7,433 | $20.30 | $150,889.90 | View Details |
| Feb 2, 2026 | RUBIN PAUL D Chief Medical Officer | Sale | 7,433 | $18.75 | $139,368.75 | View Details |
| Jan 13, 2026 | GOLDSTEIN DOV A MD Chief Financial Officer | Sale | 11,663 | $20.54 | $239,548.69 | View Details |
| Jan 13, 2026 | GOLDSTEIN DOV A MD Chief Financial Officer | Sale | 8,974 | $18.43 | $165,371.08 | View Details |
| Jan 13, 2026 | GOLDSTEIN DOV A MD Chief Financial Officer | Sale | 1,923 | $21.08 | $40,538.38 | View Details |
| Jan 13, 2026 | GOLDSTEIN DOV A MD Chief Financial Officer | Sale | 4,440 | $19.45 | $86,369.54 | View Details |
| Jan 13, 2026 | Fortney Kristen Director | Sale | 233,107 | $18.12 | $4,223,036.34 | View Details |
| Jan 2, 2026 | RUBIN PAUL D Chief Medical Officer | Sale | 7,433 | $12.85 | $95,490.26 | View Details |
2 more transactions available โ create a free account to see 12 months of history | ||||||
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
EPS
Estimated-$0.74
ActualN/A
Revenue
Estimated$1.40M
ActualN/A